Adebrelimab and SHR2554 for Resistant T-cell Lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two drugs (adebrelimab and SHR2554) for patients with T-cell or NK/T-cell lymphomas that have stopped responding to previous treatments. The goal is to see if this combination can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of peripheral T-cell lymphoma or NK/T-cell lymphoma that has returned or stopped responding to prior treatment
- Your cancer has at least one measurable tumor on imaging (CT, MRI, or PET/CT scan)
- Your overall health status allows you to be active at least part of the day (ECOG 0-2)
- Your blood counts and organ function are adequate: normal-range white blood cells, platelets, kidney/liver function
- You have not received other cancer treatments within the past 4 weeks, and no immune checkpoint inhibitors within 3 months
- You are not pregnant, do not have active infections, and are not taking systemic steroids or immunosuppressive medications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two new drugs (SHR-0302 and SHR-2554) for people with a type of lymphoma (peripheral T-cell lymphoma) that has come back or not responded to prior treatment. The goal is to see if the combination can help control the cancer.
This study tests the drug SHR2554 as a maintenance therapy for people with peripheral T-cell lymphoma who responded well to their first chemotherapy. The goal is to help keep the cancer from coming back.
This trial tests a new drug called SHR2554 (compared to chidamide) for T-cell lymphoma that has not responded to or come back after prior treatment. It's a Phase 3 study to see if the drug can help control the cancer.
This trial is testing a combination of two targeted drugs (linperlisib and an EZH2 inhibitor) for people whose peripheral T-cell lymphoma has come back or not responded to previous treatment. The goal is to see if this new combination can help shrink tumors and slow the disease.
This trial tests a new experimental antibody therapy for people with certain types of peripheral T-cell lymphoma that have not responded to or have come back after prior treatment. The study aims to see if the treatment is safe and effective.
This trial tests an experimental drug called TR115 versus your doctor's choice of standard treatment for peripheral T-cell lymphoma that has come back or stopped responding to prior treatments. TR115 may help control this rare blood cancer by targeting specific cancer pathways.
Hear when a new Relapsed or Refractory Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.